NCT04780529

CART Therapy in Digestive System Tumors

Chimeric Antigen Receptor T Cells (CART) Therapy in GUCY2C Positive Digestive System Tumors

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Innovative Cellular Therapeutics Co., Ltd. · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Chimeric Antigen Receptor T Cells (CART) Therapy in GUYC2C postive Digestive system tumors, include colorectal cancer, gastric cancer, liver cancer, pancreatic cancer, adenocarcinoma of esophagus, cancer of the esophagogastric junction. Ict-gc is an open, single-center study to evaluate the safety and efficacy of CAR-T-targeted therapy in patients with advanced gastrointestinal tumors.

Detailed description

The primary objective of phase 1 is to evaluate the safety of CART regimens. The primary objective of phase 2 is to evaluate the efficacy of CART, as measured by objective response rate in subjects with colorectal cancer. Secondary objectives will include assessing the safety and tolerability of CART and additional efficacy endpoints.

Conditions

• Malignant Neoplasms of Digestive Organs

Interventions

Type	Name	Description
BIOLOGICAL	gucy2c cart cells	Patients with advanced malignant gastrointestinal tumors were injected with CART cells

Timeline

• Start date: 2021-03-01
• Primary completion: 2022-04-01
• Completion: 2026-03-01
• First posted: 2021-03-03
• Last updated: 2021-03-03

Locations

1 site across 1 country: China